China reports first oil tanker targeted in Hormuz

 A Chinese oil tanker was attacked in the Strait of Hormuz on Tuesday, May 4, Chinese media outlet Caixin Global reported on Thursday. The event marks the first instance of a China-owned vessel being targeted in the embattled maritime chokepoint.

Iranian Foreign Minister Abbas Araghchi met his Chinese counterpart Wang Yi in Beijing on Wednesday for talks, marking his first visit to the Asian giant.

Earlier this week, the San Antonio, a container ship of the world's third-largest container shipping line, CMA CGM, was attacked while transiting ‌the vital waterway, injuring crew members and damaging the vessel.

https://breakingthenews.net/Article/China-reports-first-oil-tanker-targeted-in-Hormuz/66240838

China sentences ex-ministers to suspended death

 China sentenced former defense ministers ​Wei Fenghe and ‌Li Shangfu to ​death with ​a two-year reprieve on corruption charges, state ​media Xinhua reported ​on Thursday.

In 2024, the two men were expelled from the ruling Communist Party for "serious violations of discipline," which is a euphemism for corruption. In China, a death sentence with reprieve is usually converted to life in prison if the defendant does not commit any crimes during the reprieve time.

Li was found guilty by disciplinary bodies of "serious violation" of organizational and political discipline, including taking "huge sums of money and valuables in return" for favors. Li's predecessor as defense minister, Wei Fenghe, was also dismissed for graft-related offences.

https://breakingthenews.net/Article/China-sentences-ex-ministers-to-suspended-death/66242185

Alcon revenue miss, ups EPS growth guidance

 

Alcon reports Q1 2026 results with non-GAAP EPS $0.85 (+16% YoY) beating estimates and revenue $2.7B (+10% YoY) missing estimates

• Raises 2026 core EPS growth guidance to 10–13% from 9–12%.
• Authorizes up to $1.5 billion share repurchase program in aggregate.

https://finviz.com/quote?t=ALC&p=d#google_vignette

Nerve stimulation device maker Mobia Medical sets terms for $150 million IPO, pricing this week

 Mobia Medical, which sells a nerve stimulation device for chronic ischemic stroke, announced terms for its IPO on Monday.

The Austin, TX-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16.

Mobia's Vivistim Paired Vagus Nerve Stimulation System is the first and only clinically-validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The system includes an implanted pulse generator and lead that deliver stimulation during functional movement in order to increase neuroplasticity and durably restore motor function. Management estimates that there are over four million chronic ischemic stroke survivors, of which one million have the health, cognition, and motivation to participate in post-stroke therapy, representing a $30 billion opportunity based on the system's price.

Mobia Medical was founded in 2007 and booked $32 million in revenue for the 12 months ended December 31, 2025. It plans to list on the Nasdaq under the symbol MOBI. BofA Securities, J.P. Morgan, and Goldman Sachs are the joint bookrunners on the deal. It is expected to price the week of May 4, 2026.

Relevant Profile: MOBI

https://www.renaissancecapital.com/IPO-Center/News/118736/Nerve-stimulation-device-maker-Mobia-Medical-sets-terms-for-$150-million-IP

Emergency medical services provider GMR Solutions sets terms for $750 million IPO

GMR Solutions, a leading provider of emergency medical services and alternate-site care in the US, announced terms for its IPO on Monday.

The Lewisville, TX-based company plans to raise $750 million by offering 31.9 million shares at a price range of $22 to $25.

Formed in 2018 through the merger of Air Medical Group Holdings and American Medical Response, GMR Solutions is a provider of emergency medical services and out-of-hospital care in the United States and internationally. The company delivers on-site clinical care through trained medical teams and coordinates patient transport via air and ground ambulance when higher levels of care are required, or directs non-emergent patients to lower-acuity settings. Its operations span a broad network of urban and rural communities, functioning as an entry point into the healthcare system and supporting care delivery across a range of emergency and non-emergency situations.

GMR Solutions was founded in 2018 and booked $5.7 billion in revenue for the 12 months ended December 31, 2025. It plans to list on the NYSE under the symbol GMRS. J.P. Morgan, KKR, BofA Securities, Barclays, Goldman Sachs, Citi, Evercore ISI, Morgan Stanley, and UBS Investment Bank are the joint bookrunners on the deal. It is expected to price during the week of May 11, 2026.

Relevant Profile: GMRS

https://www.renaissancecapital.com/IPO-Center/News/118762/Emergency-medical-services-provider-GMR-Solutions-sets-terms-for-$750-milli

Quanterix maintains 2026 guidance despite steep organic declines, boosts Alzheimer’s diagnostics

 

Quanterix Q1 2026: EPS -$0.37, revenue $36.4M, maintains 2026 guidance despite steep organic declines, boosts Alzheimer’s diagnostics

• Q1 revenue was $36.4 million, +20% YoY but organic revenue declined 21%.
• Non-GAAP EPS for Q1 2026 was -$0.37, improving 30% YoY.
• Simoa revenue fell 21% organically and spatial revenue declined 26% amid tough end markets.
• Pharma revenue dropped 33% and academic revenue fell ~16% on a pro forma basis.
• Non-GAAP gross margin held at 50.9%, supported by realized Akoya cost synergies.
• Full-year 2026 revenue guidance of $169–$174 million and margin outlook were maintained.
• Management expects Q2 roughly in line with Q1 and a stronger, initiative-driven second half.
• Quanterix targets cash flow breakeven by Q4 2026, ending 2026 with about $100 million cash.
• Company is increasing investment in LucentAD Complete, expecting FDA clearance in 2H 2026.
• Upgraded HD-X platform is being prepared for IVD filing in 2027 to support diagnostics.
• Key risks are instrument softness, academic funding pressure, and execution on back-half-weighted guide.
• Main concern: Executing commercial initiatives to deliver a heavily second-half-weighted 2026 revenue plan in weak markets.
• Mixed quarter, driven by resilient margins and diagnostics progress offset by significant organic revenue pressure.

https://finviz.com/quote?t=QTRX&p=d

Recursion extends cash runway into 2028, beats as AI platform yields first clinical proof

 

Recursion extends cash runway into 2028 and posts Q1 2026 EPS -$0.22 beat as AI platform yields first clinical proof

• REC-4881 showed clinical proof-of-concept in FAP; FDA engagement underway on registrational pathway.
• Q1 2026 non-GAAP EPS -$0.22 improved 56% YoY and beat estimates.
• Q1 2026 revenue was $6.3M, down 57% YoY and below about $16M forecast for the quarter.
• Cash and equivalents $665m, with operating runway guided through early 2028 without new financing.
• Cash operating expenses down 30% YoY; 2026 cash opex guidance below $390m reaffirmed.
• Q1 2026 net loss totaled $117.5M, versus reported quarterly revenue of $6.5M.
• Early REC-1245 Phase I data show good tolerability, target engagement, and dose-dependent exposure.
• REC-4539 LSD1 inhibitor dosed first patient; aims to reduce class-limiting thrombocytopenia.
• Company expects clinical readouts for all wholly owned clinical programs over next 12–18 months.
• Platform efficiency claims: ~90% fewer compounds synthesized and roughly 2x faster to candidates.
• ClinTech tools reportedly cut trial enrollment times 30–60% and broaden eligible patient pools.
• Partnerships have generated $500m+ inflows; fifth Sanofi milestone achieved, more opt-ins anticipated.
• Main concern: long path and regulatory uncertainty before AI-derived pipeline converts into commercial revenue.
• Mixed quarter, driven by strong AI-driven pipeline and platform progress offset by continued pre-revenue status.

https://finviz.com/quote?t=RXRX&p=d